Cargando…
Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
Bacteriophages (phages) are viruses that kill bacteria specifically but cannot infect other kinds of organisms. They have attracted new attention since the increasing antibiotic resistance developed into a global crisis. Phage therapy, a 100-year-old form of antibacterial treatment in medicine, is g...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302670/ https://www.ncbi.nlm.nih.gov/pubmed/30256176 http://dx.doi.org/10.1089/sur.2018.184 |
_version_ | 1783382030848884736 |
---|---|
author | Rohde, Christine Wittmann, Johannes Kutter, Elizabeth |
author_facet | Rohde, Christine Wittmann, Johannes Kutter, Elizabeth |
author_sort | Rohde, Christine |
collection | PubMed |
description | Bacteriophages (phages) are viruses that kill bacteria specifically but cannot infect other kinds of organisms. They have attracted new attention since the increasing antibiotic resistance developed into a global crisis. Phage therapy, a 100-year-old form of antibacterial treatment in medicine, is gaining momentum because phages represent a therapy concept without such negative side effects as toxicity; phages are the only therapeutic agent that regulates itself at the sites of infection and decays when the infectious bacteria have been killed. Nature is an almost infinite phage resource: New ones can be isolated for most kinds of problem bacteria as needed; bacteria and their phages constantly co-evolve. This is important as new pathogenic bacterial variants evolve and new challenging situations arise. In human therapy, “cocktails” of multiple phages may reduce the probability of selecting bacteria that developed resistance to a certain phage. Antibiotic agents can be applied together with phages in many circumstances; the two often function synergistically. Phages cannot be expected to replace antibiotic agents in our medical arsenal, but can be used where antibiotic agents fail. The selected phages, however, must be obligately virulent, well-characterized, and highly purified before application. Countless patients and their physicians are waiting for re-establishing phage therapy as a flexible, tailored medicine; infrastructures should be built in all countries urgently: The 2015 World Health Organization assembly resolution 68.7.3. called for national action plans by May 2017 to combat the antimicrobial drug resistance crisis. This article discusses the therapeutic potential of phages and describes challenges and recent developments. |
format | Online Article Text |
id | pubmed-6302670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-63026702018-12-26 Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria Rohde, Christine Wittmann, Johannes Kutter, Elizabeth Surg Infect (Larchmt) Invited Reviews Bacteriophages (phages) are viruses that kill bacteria specifically but cannot infect other kinds of organisms. They have attracted new attention since the increasing antibiotic resistance developed into a global crisis. Phage therapy, a 100-year-old form of antibacterial treatment in medicine, is gaining momentum because phages represent a therapy concept without such negative side effects as toxicity; phages are the only therapeutic agent that regulates itself at the sites of infection and decays when the infectious bacteria have been killed. Nature is an almost infinite phage resource: New ones can be isolated for most kinds of problem bacteria as needed; bacteria and their phages constantly co-evolve. This is important as new pathogenic bacterial variants evolve and new challenging situations arise. In human therapy, “cocktails” of multiple phages may reduce the probability of selecting bacteria that developed resistance to a certain phage. Antibiotic agents can be applied together with phages in many circumstances; the two often function synergistically. Phages cannot be expected to replace antibiotic agents in our medical arsenal, but can be used where antibiotic agents fail. The selected phages, however, must be obligately virulent, well-characterized, and highly purified before application. Countless patients and their physicians are waiting for re-establishing phage therapy as a flexible, tailored medicine; infrastructures should be built in all countries urgently: The 2015 World Health Organization assembly resolution 68.7.3. called for national action plans by May 2017 to combat the antimicrobial drug resistance crisis. This article discusses the therapeutic potential of phages and describes challenges and recent developments. Mary Ann Liebert, Inc., publishers 2018-11-01 2018-12-05 /pmc/articles/PMC6302670/ /pubmed/30256176 http://dx.doi.org/10.1089/sur.2018.184 Text en © Christine Rohde et al., 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Invited Reviews Rohde, Christine Wittmann, Johannes Kutter, Elizabeth Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria |
title | Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria |
title_full | Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria |
title_fullStr | Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria |
title_full_unstemmed | Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria |
title_short | Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria |
title_sort | bacteriophages: a therapy concept against multi-drug–resistant bacteria |
topic | Invited Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302670/ https://www.ncbi.nlm.nih.gov/pubmed/30256176 http://dx.doi.org/10.1089/sur.2018.184 |
work_keys_str_mv | AT rohdechristine bacteriophagesatherapyconceptagainstmultidrugresistantbacteria AT wittmannjohannes bacteriophagesatherapyconceptagainstmultidrugresistantbacteria AT kutterelizabeth bacteriophagesatherapyconceptagainstmultidrugresistantbacteria |